Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

Trial Identifier: D5160C00036
Sponsor: AstraZeneca
NCTID:: NCT02908750
Start Date: March 2017
Primary Completion Date: July 2017
Study Completion Date: October 2022
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
French Translation
Korean Translation
Spanish Translation

Trial Locations

Country Location
ES Madrid, ES, 28040
ES Madrid, ES, 28046
ES Madrid, ES, 28050
ES Sevilla, ES, 41013
FR Rennes Cedex 9, FR, 35033
KR Seongnam-si, KR, 13620
KR Seoul, KR, 05505